Key Points
- Director Christopher Kiritsy sold 313 Palvella Therapeutics shares at an average price of $157, generating $49,141 and reducing his position by 55.6% to 250 shares.
- PVLA opened at $157.24, near its 52-week high of $161.38, with a $2.27 billion market capitalization. The company reported a quarterly loss of $1.52 per share, missing the $1.17 analyst consensus.
- Analysts maintain an overall “Buy” rating with a consensus price target of $209.14, while institutional investors and hedge funds own 40.11% of the stock.
Palvella Therapeutics, Inc. (NASDAQ:PVLA - Get Free Report) Director Christopher Kiritsy sold 313 shares of the company's stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $157.00, for a total value of $49,141.00. Following the sale, the director owned 250 shares of the company's stock, valued at approximately $39,250. This trade represents a 55.60% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Palvella Therapeutics Stock Performance
Shares of PVLA stock opened at $157.24 on Friday. The stock's 50 day simple moving average is $148.35 and its 200 day simple moving average is $129.46. Palvella Therapeutics, Inc. has a twelve month low of $52.36 and a twelve month high of $161.38. The company has a market capitalization of $2.27 billion, a price-to-earnings ratio of -32.55 and a beta of -0.25.
Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) last announced its earnings results on Tuesday, August 4th. The company reported ($1.52) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.35). On average, analysts forecast that Palvella Therapeutics, Inc. will post -6.36 EPS for the current fiscal year.
Hedge Funds Weigh In On Palvella Therapeutics
Several large investors have recently bought and sold shares of the stock. California State Teachers Retirement System boosted its holdings in Palvella Therapeutics by 24,639.3% in the 2nd quarter. California State Teachers Retirement System now owns 1,705,777 shares of the company's stock valued at $260,677,000 after purchasing an additional 1,698,882 shares during the period. First Light Asset Management LLC raised its position in shares of Palvella Therapeutics by 38.3% during the first quarter. First Light Asset Management LLC now owns 980,758 shares of the company's stock valued at $122,251,000 after buying an additional 271,617 shares during the last quarter. BlackRock Inc. bought a new stake in shares of Palvella Therapeutics in the second quarter valued at about $140,343,000. Suvretta Capital Management LLC lifted its stake in shares of Palvella Therapeutics by 8.5% in the fourth quarter. Suvretta Capital Management LLC now owns 892,400 shares of the company's stock valued at $93,408,000 after buying an additional 70,000 shares during the period. Finally, Jennison Associates LLC grew its position in Palvella Therapeutics by 65.3% during the first quarter. Jennison Associates LLC now owns 640,611 shares of the company's stock worth $79,852,000 after buying an additional 253,128 shares in the last quarter. 40.11% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
A number of research analysts recently issued reports on PVLA shares. Truist Financial set a $207.00 target price on shares of Palvella Therapeutics in a research note on Wednesday, August 5th. Chardan Capital upgraded shares of Palvella Therapeutics to a "strong-buy" rating in a report on Tuesday, July 28th. HC Wainwright reaffirmed a "buy" rating and issued a $270.00 price target on shares of Palvella Therapeutics in a research report on Wednesday, July 22nd. Weiss Ratings reiterated a "sell (d-)" rating on shares of Palvella Therapeutics in a research note on Monday, June 29th. Finally, Stephens reissued an "overweight" rating and set a $220.00 price objective on shares of Palvella Therapeutics in a research report on Thursday, May 21st. Two investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, Palvella Therapeutics currently has an average rating of "Buy" and a consensus target price of $209.14.
Check Out Our Latest Report on Palvella Therapeutics
About Palvella Therapeutics
(
Get Free Report)
Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.
Palvella's pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
